Latest Ratios: P/E Ratio 23.2x · EV/EBITDA 2.7x · ROE 48.1%. (2022–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Market Cap | $3.9B | $2.5B | $2.5B | — | — |
| Enterprise Value | $5.9B | $4.5B | $4.3B | — | — |
| P/E Ratio → | 23.19 | 15.14 | 15.22 | — | — |
| P/S Ratio | 1.78 | 1.17 | 1.33 | — | — |
| P/B Ratio | 9.19 | 6.00 | 8.48 | — | — |
| P/FCF | 19.58 | 12.80 | 12.05 | — | — |
| P/OCF | 13.81 | 9.03 | 9.23 | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| EV / Revenue | — | 2.10 | 2.26 | — | — |
| EV / EBITDA | 2.72 | 2.10 | 11.57 | — | — |
| EV / EBIT | 2.82 | 13.65 | 14.29 | — | — |
| EV / FCF | — | 23.06 | 20.45 | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Gross Margin | 28.3% | 28.3% | 27.8% | 27.9% | 23.7% |
| Operating Margin | 96.5% | 96.5% | 16.0% | 15.6% | 15.0% |
| Net Profit Margin | 8.0% | 8.0% | 8.8% | 9.8% | 9.7% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| ROE | 48.1% | 48.1% | 22.6% | 16.6% | 16.7% |
| ROA | 6.2% | 6.2% | 6.6% | 7.5% | 7.3% |
| ROIC | 69.4% | 69.4% | 11.1% | 10.7% | 9.7% |
| ROCE | 84.9% | 84.9% | 13.8% | 13.6% | 12.8% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Debt / Equity | 5.00 | 5.00 | 6.53 | 0.77 | 1.04 |
| Debt / EBITDA | 0.97 | 0.97 | 5.25 | 2.51 | 3.13 |
| Net Debt / Equity | — | 4.81 | 5.92 | 0.74 | 1.01 |
| Net Debt / EBITDA | 0.93 | 0.93 | 4.75 | 2.42 | 3.02 |
| Debt / FCF | — | 10.26 | 8.41 | 5.30 | 4.39 |
| Interest Coverage | 3.05 | 3.05 | 4.32 | 2.52 | 8.11 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Current Ratio | 1.14 | 1.14 | 1.42 | 1.07 | 1.02 |
| Quick Ratio | 1.14 | 1.14 | 1.42 | 1.07 | 1.02 |
| Cash Ratio | 0.24 | 0.24 | 0.60 | 0.11 | 0.13 |
| Asset Turnover | — | 0.71 | 0.75 | 0.74 | 0.75 |
| Inventory Turnover | — | — | — | — | — |
| Days Sales Outstanding | — | 43.51 | 41.82 | 42.93 | 43.66 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Dividend Yield | 0.8% | 1.3% | 60.9% | — | — |
| Payout Ratio | 18.6% | 18.6% | 926.9% | 3.4% | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Earnings Yield | 4.3% | 6.6% | 6.6% | — | — |
| FCF Yield | 5.1% | 7.8% | 8.3% | — | — |
| Buyback Yield | 0.6% | 0.9% | 0.6% | — | — |
| Total Shareholder Yield | 1.4% | 2.2% | 61.5% | — | — |
| Shares Outstanding | — | $128M | $128M | $127M | $127M |
High leverage and goodwill
Based on current market data, Concentra trades at a forward P/E of 19.87, which appears to command a premium relative to peers like Select Medical, suggesting that investors are pricing in significant growth expectations that may not be fully supported by the company's recent volatile earnings performance.
The current valuation multiples appear to reflect a market expectation of durable B2B service growth, yet the lack of a clear PEG ratio and the volatility in historical earnings suggest that this premium may be fragile. Investors should monitor whether the company can sustain its current growth trajectory to justify these multiples, particularly as it navigates its new status as a standalone public entity.
According to recent financial statements, Concentra's ROIC has remained consistently low, hovering near 2.9% in 2026Q1, which indicates that the company is struggling to generate meaningful returns on its invested capital base compared to the higher efficiency levels observed in specialized healthcare service peers.
The persistent gap between the company's cost of capital and its actual ROIC suggests that the current business model may be capital-intensive without providing commensurate returns. This trend warrants further investigation into whether the high goodwill concentration is masking a fundamental decay in the underlying operational efficiency of the clinic network.
As reported in recent filings, the company's asset turnover ratio has remained stagnant at approximately 0.19, highlighting a persistent inability to scale revenue efficiently relative to its physical clinic footprint and the significant administrative overhead required to manage its complex workers' compensation billing processes.
The stability of the DSO around 44 days suggests that while the company maintains a consistent collection cycle, it has not yet achieved the operational leverage necessary to improve its asset utilization. This lack of improvement in turnover implies that the company's growth is primarily driven by physical expansion rather than gains in internal process efficiency.
Based on the company's reported figures, the debt-to-equity ratio has surged to 4.68 as of 2026Q1, representing a significant increase from historical levels and signaling a shift toward a more leveraged capital structure that may constrain future strategic investments or bolt-on acquisitions.
The rapid accumulation of debt following the separation from Select Medical appears to have placed the company in a more vulnerable position, as evidenced by the fluctuating interest coverage ratio. Investors should monitor whether the current cash flow generation is sufficient to service this debt load without requiring further capital market intervention.
The 96.50% operating margin often cited in public data feeds is a highly misleading metric for this business model, as it likely reflects non-recurring accounting artifacts from the IPO process rather than the true, lower normalized earning power of the company's occupational health clinics.
Analysts frequently misapply this headline margin to project future profitability, failing to account for the high fixed costs of clinical labor and the reality of state-mandated reimbursement caps. A more accurate assessment of the company's earning power requires adjusting for these one-time items to reveal the underlying margin pressure inherent in the occupational health sector.
Includes 30+ ratios · 4 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying CON stock.
Concentra Group Holdings Parent, Inc.'s current P/E ratio is 23.2x. The historical average is 15.2x. This places it at the 100th percentile of its historical range.
Concentra Group Holdings Parent, Inc.'s current EV/EBITDA is 2.7x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 6.8x.
Concentra Group Holdings Parent, Inc.'s return on equity (ROE) is 48.1%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is 26.0%.
Based on historical data, Concentra Group Holdings Parent, Inc. is trading at a P/E of 23.2x. This is at the 100th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Concentra Group Holdings Parent, Inc.'s current dividend yield is 0.83% with a payout ratio of 18.6%.
Concentra Group Holdings Parent, Inc. has 28.3% gross margin and 96.5% operating margin. Operating margin above 20% indicates strong pricing power and cost efficiency.
Concentra Group Holdings Parent, Inc.'s Debt/EBITDA ratio is 1.0x, indicating low leverage. A ratio below 2x is generally considered financially healthy.